DWTX READ THE FULL DWTX RESEARCH REPORT Business Update Positive Interim Results for Phase 2b Trial of Halneuron® in CINP On ...

Roche RHHBY announced positive data from the late-stage lidERA Breast Cancer study on pipeline candidate giredestrant. Giredestrant is an investigational, oral, potent next-generation selective ...

Arvinas, Inc. reported positive topline results from its Phase 3 VERITAC-2 trial for vepdegestrant, supporting global regulatory filings aimed at treating metastatic breast cancer. The company also ...

I-Mab reported positive Phase 1b study results for givastomig in metastatic gastric cancers, highlighting significant efficacy and a favorable safety profile. I-Mab has announced positive results from ...

Corvus Pharmaceuticals (CRVS) is in the process of evaluating the use of its interleukin-2-inducible T cell kinase [ITK] inhibitor for the treatment of patients with a wide variety of lymphoma types, ...

Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The mRNA shot stacked up well against a licensed ...

– Phase III ALLEGORY study met primary and all key secondary endpoints with Gazyva, an anti-CD20 monoclonal antibody designed for enhanced B cell depletion – – Gazyva has the potential to be a ...

Kymera Therapeutics, Inc. (KYMR) just reported positive results from its phase 1 healthy volunteer study using KT-621. The purpose of this clinical candidate is to develop it as an oral STAT6 protein ...

Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or ...

Altimmune, Inc. (NASDAQ:ALT) is one of Goldman Sachs’ top penny stock picks. On June 26, the company reported positive topline results from its Phase 2b IMPACT trial evaluating Pemvidutide, a ...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) today announced positive topline results from its pivotal Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of ...